Stockreport

KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF KT-621 is an investigational, first-in-class, once-daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central [Read more]